Altimmune Management

Management criteria checks 2/4

Altimmune's CEO is Vipin Garg, appointed in Nov 2018, has a tenure of 5.67 years. total yearly compensation is $5.48M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $1.93M. The average tenure of the management team and the board of directors is 5 years and 5.8 years respectively.

Key information

Vipin Garg

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage	11.3%
CEO tenure	5.7yrs
CEO ownership	0.4%
Management average tenure	5yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vipin Garg's remuneration changed compared to Altimmune's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$5m	US$620k	-US$88m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$580k	-US$85m
Sep 30 2022	n/a	n/a	-US$87m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$102m
Dec 31 2021	US$3m	US$566k	-US$97m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$514k	-US$49m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$815k	US$500k	-US$21m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$34m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$44k	-US$42m

Compensation vs Market: Vipin's total compensation ($USD5.48M) is above average for companies of similar size in the UK market ($USD978.80K).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

CEO

Vipin Garg (66 yo)

5.7yrs

Tenure

US$5,482,089

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vipin Garg	President	5.7yrs	US$5.48m	0.41% $ 1.9m
Matthew Harris	Chief Medical Officer	5yrs	US$2.24m	0.076% $ 354.0k
Raymond Jordt	Chief Business Officer	1.5yrs	US$2.94m	0.019% $ 90.7k
Bertrand Georges	Chief Technology Officer	7.2yrs	no data	no data
M. Roberts	Chief Scientific Officer	11.6yrs	US$1.41m	0.060% $ 281.7k
Tony Blandin	Vice President of Quality & Compliance Management	2.4yrs	no data	no data
Andrew Shutterly	Corporate Controller	1.4yrs	no data	0.014% $ 66.7k

5.0yrs

Average Tenure

65.5yo

Average Age

Experienced Management: 0A4C's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Vipin Garg	President	5.7yrs	US$5.48m	0.41% $ 1.9m
Mitchel Sayare	Independent Chairman	14.3yrs	US$119.68k	0.037% $ 174.0k
John Gill	Independent Director	19.9yrs	US$103.68k	0.0039% $ 18.3k
David Drutz	Independent Director	7.2yrs	US$109.68k	0.042% $ 196.6k
Philip Hodges	Independent Director	7.2yrs	US$115.68k	0.037% $ 175.4k
Klaus Schafer	Independent Director	7.2yrs	US$104.68k	0.013% $ 60.6k
Wayne Pisano	Independent Director	5.9yrs	US$108.68k	0.012% $ 56.1k
Diane Jorkasky	Independent Director	4.2yrs	US$95.68k	0% $ 0
Rohit Loomba	Member of Mash Scientific Advisory Board	2yrs	no data	no data
Michael Charlton	Member of Mash Scientific Advisory Board	2yrs	no data	no data
Mazen Noureddin	Member of Mash Scientific Advisory Board	2yrs	no data	no data
Naga Chalasani	Member of Mash Scientific Advisory Board	2yrs	no data	no data

5.8yrs

Average Tenure

72yo

Average Age

Experienced Board: 0A4C's board of directors are considered experienced (5.8 years average tenure).

Altimmune Management

Management criteria checks 2/4

Key information

Recent management updates

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Insufficient new directors

Insufficient new directors

Recent updates

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.66 loss per share (vs US$1.81 loss in FY 2022)

New major risk - Revenue and earnings growth

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

New major risk - Share price stability

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.48 loss in 3Q 2022)

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.60 loss in 2Q 2021)

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2021)

Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022

Insufficient new directors

Insufficient new directors

Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Insufficient new directors

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.54 loss in 3Q 2020)

Altimmune Announces Positive Results from 12-Week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

Altimmune, Inc. Reports an Impairment on Construction-In-Progress for the Three Months Ended June 30, 2021

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 2Q 2020)

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Forecast breakeven pushed back to 2024

Altimmune, Inc. Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

First quarter 2021 earnings released: US$0.38 loss per share (vs US$0.26 loss in 1Q 2020)

Forecast breakeven pushed back to 2025

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Altimmune, Inc. Announces Additional Preclinical Data for Its Single Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Full year 2020 earnings released: US$1.91 loss per share (vs US$1.60 loss in FY 2019)

Revenue beats expectations

Altimmune, Inc. Commences Enrollment in Phase 1 Clinical Trial of AdCOVID- A Needle-Free, Single-Dose Intranasal Covid-19 Vaccine Candidate

Altimmune, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Altimmune, Inc. Announces FDA Clearance of AdCOVID™ IND Application

Altimmune, Inc. Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

Altimmune Announces Submission of Investigational New Drug Application To the U.S. Food and Drug Administration to Commence A Phase 1 Clinical Study of Its Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

Altimmune, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Altimmune and UAB Announces Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age